Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The MEK inhibitor trametinib incurs mitochondrial injury and induces innate immune responses in the mouse heart.

Science advances·2026
Same author

Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2).

NPJ breast cancer·2026
Same author

Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions.

Vaccines·2026
Same author

TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in <i>PALB2</i> or Somatic Mutations in <i>BRCA1</i> or <i>BRCA2</i>.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.

The New England journal of medicine·2026
Same author

Management of Cancer During Pregnancy: ASCO Guideline.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Related Experiment Video

Updated: Aug 31, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.1K

Triple negative breast cancer: Pitfalls and progress.

Paola Zagami1,2, Lisa Anne Carey3

  • 1Department of Oncology and Hematology, University of Milano, Milan, Italy.

NPJ Breast Cancer
|August 20, 2022
PubMed
Summary

Triple negative breast cancer (TNBC) lacks targeted therapies and has a poor prognosis. Advances in chemotherapy and immunotherapy have improved outcomes, but more research is needed for specific treatments.

More Related Videos

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

6.2K
Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence
06:52

Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence

Published on: November 5, 2021

3.2K

Related Experiment Videos

Last Updated: Aug 31, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.1K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

6.2K
Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence
06:52

Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence

Published on: November 5, 2021

3.2K

Area of Science:

  • Oncology
  • Genetics
  • Epidemiology

Background:

  • Triple negative breast cancer (TNBC) comprises 10-15% of breast cancers.
  • TNBC is characterized by negative estrogen receptor, progesterone receptor, and HER2 expression.
  • It disproportionately affects Black and pre-menopausal women, carrying a worse prognosis and significant patient burdens.

Purpose of the Study:

  • To review the current understanding of TNBC biology and treatment landscape.
  • To highlight the unmet need for targeted therapies in TNBC.
  • To discuss future directions for TNBC research and clinical management.

Main Methods:

  • Literature review of TNBC epidemiology, biology, and therapeutic strategies.
  • Analysis of current treatment advancements, including chemotherapy and immunotherapy.
  • Discussion of future research priorities for TNBC.

Main Results:

  • TNBC is biologically heterogeneous, lacking specific targeted therapies unlike other breast cancer subtypes.
  • Recent therapeutic intensification, including chemotherapy and immunotherapy, has improved early-stage TNBC outcomes.
  • Significant challenges remain, including preventing immune evasion and addressing socioeconomic burdens.

Conclusions:

  • Despite recent advances, TNBC remains a challenging diagnosis due to its heterogeneity and lack of targeted treatments.
  • Future research should focus on identifying targetable molecular aberrations and improving supportive care.
  • The ultimate goal is to move beyond the current TNBC classification towards therapies targeting specific molecular entities.